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Summary
Objective: To test the effects of chondroitin sulfate (ACS, a glycosaminoglycan of cartilage) with and without
interleukin-1b (IL-1b) on human articular chondrocytes cultivated in clusters and in long-term (0–16 days or 16–32
days).
Design: Chondrocyte productions of proteoglycans (PGs), type II collagen (coll-II) and prostaglandin E2 (PGE2) were
assayed by specific radioimmunoassays applied to conditioned culture media and to clusters.
Results: During the two culture periods (0–16 days or 16–32 days), ACS (100–1000 mg/ml) increased total PG
production and had no effect on the production of coll-II by chondrocytes. During the first 16 days, ACS
(500–1000 mg/ml) decreased total PGE2 synthesis. IL-1b decreased PG and coll-II productions and increased PGE2
synthesis. During the first period (0–16 days), while the cluster is forming, ACS counteracted the IL-1b-induced effects
on PG (500–1000 mg ACS/ml), coll-II (100–1000 mg ACS/ml) and PGE2 (500–1000 mg ACS/ml) productions. During the
second period (16–32 days), when the cluster is already formed, ACS counteracted the IL-1b-induced effects on total
PG (100–1000 mg ACS/ml), coll-II (1000 mg ACS/ml) and PGE2 (1000 mg ACS/ml) productions.
Conclusions: These in vitro studies suggest that ACS is able to increase matrix component production by human
chondrocytes and to inhibit the negative effects of IL-1b.
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Introduction
Articular cartilage is a connective tissue com-
posed of cells (chondrocytes) located inside a
matrix essentially constituted by proteoglycans
(PGs) and type II collagen (coll-II) [1]. Cartilage is
subject to anabolic processes (chondroformation)
and catabolic processes (chondroresorption).
Chondrocytes are able to maintain a dynamic
equilibrium between these processes. In
articular diseases, such as in osteoarthritis (OA),
catabolic processes exceed anabolic processes,
leading to a net decrease of matrix material
[2]. Anabolic and catabolic processes are influ-
enced by agents such as cytokines, hormones,
growth factors and precursors of matrix el-
ements. Interleukin-1 (IL-1) is a cytokine that
is involved in the cartilage degradation [3]. IL-1
is produced by various cell types (monocytes,
macrophages, chondrocytes, etc.) [4] and has
been detected in synovial fluid of patients with OA
[5]. IL-1 influences chondrocyte metabolism: it
induces prostaglandin E2 (PGE2) production [6]
and protease activation and production (e.g.,
metalloproteases such as collagenase and
stromelysin) [7].
We have previously described a system of
three-dimensional culture of chondrocytes [8]. This
culture model allows enzymatically isolated hu-
man chondrocytes to aggregate and form a cluster.
In the cluster, chondrocytes are morphologically
and biosynthetically differentiated (cells with a
round shape located inside a newly synthesized
matrix composed of coll-II and cartilage PGs
[8–12]). In this culture model there are two phases:
the cluster formation (a large production of matrix
components taking place during the first 2 weeks),
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then a decrease in matrix component production
when cells are surrounded by the matrix.
In this work, we have studied the in vitro effects
of chondroitin sulfate (ACS) on human articular
chondrocytes. These cells were extracted from
osteoarthritic femoral head cartilage and culti-
vated in clusters in the presence or in the absence
of IL-1b, during the first 16 days of culture or
from day 16 to day 32. By use of specific and
sensitive radioimmunoassays, we have studied
the effects of ACS 2 IL-1b on two anabolic
processes (PG and coll-II production in con-
ditioned culture media and inside clusters) and
PGE2 production.
Materials and Methods
three-dimensional culture of human
chondrocytes
The effects of ACS 2 IL-1b were assessed in
human chondrocytes in culture, according to a
previously defined methodology [8]. Human chon-
drocytes were cultivated in Dulbecco’s modified of
Eagle’s medium, supplemented with 1% Ultroser G
(Gibco, Gent, Belgium) and 50 mg/ml ascorbate.
Macroscopically healthy cartilage was taken from
three osteoarthritic human femoral heads, immedi-
ately after surgery for total hip prostheses (mean
age of the patients: 65 years). Histological analyses
of cartilage from these samples showed some
typical osteoarthritic modifications such as clus-
ters of chondrocytes, loss of metachromasy and
fibrillation. Cartilage was digested by 1 mg/ml
clostridial collagenase (Boehringer Mannheim
GmbH, Germany) in buffer (NaCl 120 mmol/l,
KH2PO4 5 mmol/l, NaHCO3 25 mmol/l, glucose
3 mmol/l and Hepes 30 mmol/l, pH 7.4) for
24 h. After six successive washings and centrifuga-
tions, the cells were suspended in glass flasks
(Sovirel; 106 cells/2 ml culture medium) and placed
on a gyrotary shaker (100 rpm). Cultures were
maintained at 37° C in a 95% air/5% CO2
atmosphere.
Chondroitin sulfate (ACS, Structum8, 24 kDa;
Pierre Fabre Me´dicament, France) was extracted
from bovine cartilage. The product, chondroitin
sulfate, has been characterized, using various
analytical methods (high performance liquid
chromatography, electrophoreses). These analyses
clearly showed a high level of purity (q98%). No
other glycosaminoglycan (GAG) has been detected
in the preparation. No proteins were detected
either by gel electrophoresis or by Lowry and
Bradford methods in the final ACS preparation.
Assays of amino acids showed levels Q0.1% for five
amino acids. The extraction process including
acidic and basic phases can definitely exclude the
presence of agents such as growth factors or
cytokines. The ACS-4:ACS-6 ratio is approxima-
tively 1.5. ACS (0, 100, 500, 1000 mg/ml) with or
without human recombinant IL-1b (Boehringer
Mannheim GmbH, Germany; 2 IU/ml) was added to
and maintained in the culture medium throughout
the whole culture duration (0–16 days) or from day
16 to day 32. Culture media were renewed every 4
days. For each concentration of the drug and for
corresponding controls, four flasks were used; each
flask contained one chondrocyte cluster obtained
from 2106 isolated chondrocytes.
PGs, coll-II and PGE2 were radioimmunologi-
cally assayed in conditioned culture media and in
clusters. At the end of the culture, the chondrocyte
clusters were prepared for further fluorimetric
DNA assay and for radioimmunoassays, as follows:
chondrocyte clusters were washed three times with
phosphate-buffered saline (PBS: PO4 0.05 mol/l,
NaCl 0.15 mol/l, pH 7.4 ), then homogenized in
PBS in the presence of protease inhibitors [13],
sodium azide 6.7 · 10 - 3 mol/l and superoxide
dismutase (200 U/ml) by ultrasonic dissociation for
two 30-s intervals at 4 ° C (power: 200 W/cm2). The
protease inhibitors were 6-amino-hexanoic acid
0.1 mol/l, EDTA 0.01 mol/l, benzamidine chlorhy-
drate 0.05 mol/l, trypsin inhibitor 5 · 10 - 8 mol/l.
pg assay
PGs released into culture media and chondro-
cyte clusters contents were radioimmunologically
assayed according to a previously described
method [14]. Briefly, human cartilage PG were
extracted according to the methods of Roughley
et al. [15] and Bayliss and Venn [16]. Antiserum
against human cartilage PG was raised in rabbits
according to the method of Vaitukaitis et al. [17].
The radioimmunoassay was performed in a 0.4 ml
incubation volume consisting of 0.1 ml tracer
solution (15 000–20 000 cpm [125I]-PG labeled by
the chloramine-T method) [18], 0.1 ml anti-PG
antiserum diluted 1:5000 in PBS, 0.15 mol/l
NaCl, pH 7.4) containing 5 g/l bovine serum
albumin (incubation buffer) and 0.2 ml of serial
dilutions of conditioned culture media, cluster
extracts or of unlabeled antigen ranging from 0.1
to 500 ng/tube (reference curve). After 4 days at
4° C, the labeled PG-antibody complexes were
separated by double precipitation [19]. The
analytical sensitivity of the radioimmunoassay
was 0.6 ng/tube. The intra- and inter-assay coeffi-
cients of variation were less than 10 and 20%,
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Table I
Binding measures performed
Receptor Cell culture Reference molecule Bibliographic reference
IL-1b Balb/c 3T3 IL-1b Bird et al. [25]
IL-1a CHO cells IL-1a Horuk [26]
respectively, along the linear part of the curve.
As proven by digestion experiments and the
absence of cross-reactivity of GAGs, the antibodies
were solely directed against the antigenic determi-
nants of the PG core protein. In addition,
there were no interference of coll-II, fibronectin,
ACS or hyaluronic acid with the assay [14].
ACS (up to 10 mg/mL) did not cross-react in the
assay.
coll-ii assay
Type II collagen was assayed radioimmunologi-
cally according to a previously described method-
ology [20]. Briefly, coll-II was extracted from
human articular cartilage [21] and used as
immunogen, tracer and reference preparation. A
polyclonal antiserum was obtained in the guinea-
pig. The radioimmunoassay was performed in a
sequential manner. First, 0.1 ml incubation buffer
(PBS; 0.3 mol/l NaCl, pH 7.4), 0.1 ml of coll-II
reference solution (1–500 ng), culture media or
cluster extracts and 0.1 ml guinea-pig antiserum
(1:5000) were mixed. Second, 0.1 ml [125I]-labeled
coll-II (using the Iodogen method [22] and diluted
to obtain 20 000 cpm) was added. After 18 h at 4° C,
the labeled PG-antibody complexes were separated
by double precipitation [19]. Cartilage PG,
fibronectin, laminin, type I or type III collagen,
GAGs did not interfere in the assay. The detection
limit of the assay was 20 ng/ml. Intra- and
inter-assay coefficients of variation were 8 and
15% respectively.
dna assay
Cluster DNA content was assayed according to
the fluorimetric method of Labarca and Paigen
[23]. This method is based on the principle of a
fluorescent emission when the reactive
(fluorochrome-bis-benzimidazol, Calbiochem-
Behring, La Jolla, CA, U.S.A.; Hoechst dye 33258)
is bound to DNA.
prostaglandin e2 assay
Prostaglandin E2 was assayed in conditioned
culture media according to a radioimmunoassay
previously described [24]. Briefly, a polyclonal
antiserum was obtained in the rabbit. The
[3H]-PGE2 tracer came from Amersham. This tracer
was diluted in the incubation buffer in order to
obtain 100 000 cpm/ml. The PGE2 standard came
from Sigma Chemical Corporation (Saint Louis,
U.S.A.). The incubation buffer was composed of
Tris-HCl 0.01 mol/l, NaCl 0.15 mol/l, gelatin 1 g/l,
pH 7.4. To 0.1 ml of the sample to be assayed or to
the cold reference antigen (0–2500 pg/ml) were
added successively 0.1 ml buffer, 0.1 ml [3H]-PGE2
(100 000 cpm/ml) and 0.1 ml antiserum (diluted at
1:4000). After 48 h at 4 ° C, the free antigen was
separated from the antigen bound to antibodies by
charcoal (5 g/l) and dextran T70 (500 mg/l) precipi-
tation. There was no cross-reaction between this
antiserum anti-PGE2 and other prostanoids,
nor with other fatty acids. The detection limit of
the assay was 20 pg/ml. Intra- and inter-assay
coefficients of variation were 6 and 10% respect-
ively.
measures of acs binding to il-1b
The binding measures were performed as in
Table I. Experimental conditions are summarized
as in Table II. After the incubation, monolayer
cells were washed with cold buffer. Fixated
radioactivity was measured with a liquid scintil-
lation counter (Packard) using scintillant liquid
(Microscint 0) [25, 26].
Table II
Summary of experimental conditions
Receptor Ligand Concentration Nonspecific Incubation
IL1-b [125I]-IL-1b 0.1 nm IL-1b (10 nm) 240 min/4° C
IL-1a [125I]-IL-1a 60 pm IL-1a (4.4 nm) 195 min/37° C
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calculation and statistical analysis
The mean 2 s.d of each variable (released
proteoglycans, coll-II, PGE2 in culture media and
cluster contents) was calculated. Comparison of
mean values was performed using the analysis of
variance (ANOVA) test. The results were ex-
pressed as amounts measured in culture media per
microgram of DNA, and as cluster contents per
microgram DNA.
Results
proteoglycan and type II collagen productions
Results concerning proteoglycan and type II
collagen assayed in culture media and clusters for
cultures incubated with ACS 2 IL-1b at each time
point are presented in Figs 1, 2, 3, 4.
Three-dimensional culture during the first 16
days of culture PG production
When chondrocytes are cultivated in the
presence of ACS (100, 500, 1000 mg/ml), ACS
significantly increases (P Q 0.05) total PG pro-
duction in media (0–16 days) and inside chondro-
cyte clusters (at day 16) (Fig. 1).
IL-1b (2 IU/ml) induces a significant decrease of
total PG production in culture media and inside
chondrocyte clusters (IL-1b vs controls: P Q 0.05)
(Fig. 1).
When chondrocytes are cultivated in the
presence of ACS and IL-1b, ACS (500–1000 mg/ml)
Fig. 1. PG production [(a) in culture medium; (b) in
clusters] by human chondrocytes cultivated in clusters
in the presence of ACS 2 IL-1b during the first 16 days
of culture. b and c vs a; b vs c; d vs b: P Q 0.05.
Fig. 2. Coll-II production [(a) in culture medium; (b) in
clusters] by human chondrocytes cultivated in clusters
in the presence of ACS 2 IL-1b during the first 16 days
of culture. a vs b: P Q 0.05.
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Fig. 3. PG production [(a) in culture medium; (b) in
clusters] by human chondrocytes cultivated in clusters
in the presence of ACS 2 IL-1b, from day 16 to day 32. b
and c vs a; b vs c; d vs b and c: P Q 0.05.
IL-1b (P Q 0.05). ACS (100, 500, 1000 mg/ml) inhibits
the IL-1b-induced effects (IL-1b vs ACS 100 + IL-1b
or vs ACS 500 + IL-1b or vs ACS 1000 + IL-1b:
P Q 0.05) (Fig. 2).
Three-dimensional culture from day 16 to day 32
PG production
When chondrocytes are cultivated in the
presence of ACS (100, 500, 1000 mg/ml), ACS
significantly increases (P Q 0.05) total PG pro-
duction in media (P Q 0.05) (Fig. 3).
IL-1b (2 IU/ml) induces a significant decrease of
PG production in culture media (IL-1b vs controls:
P Q 0.05) and inside chondrocyte clusters at day 32
(IL-1b vs controls: P Q 0.05) (Fig. 3).
As compared to controls, total PG production in
culture media (from day 16 to day 32) is decreased
by IL-1b (P Q 0.05), is increased by ACS (100, 500 or
1000 mg/ml). ACS (at 100, 500 or 1000 mg/ml) has no
effect on the PG amount in clusters. ACS (at 100,
500 or 1000 mg/ml) counteracts the IL-1b-induced
effects IL-1b vs IL-1b + ACS 100 mg/ml or vs
IL-1b + ACS 500 mg/ml or vs IL-1b + ACS 1000 mg/
ml: P Q 0.05) (Fig. 3).
Coll-II production
Coll-II production in culture media after 16 days
of culture is not detectable by our radioimmuno-
assay (sensitivity: 20 ng/ml).
When human chondrocytes are cultivated in the
presence of ACS (100, 500 or 1000 mg/ml), ACS
does not affect coll-II production inside clusters
(Fig. 4).
Fig. 4. Coll-II inside human chondrocyte clusters
cultivated in the presence of ACS 2 IL-1b from day 16 to
day 32. a vs b; b vs c: P Q 0.05.
counteracts the IL-1b-induced effects, in culture
media and in the clusters (IL-1b vs IL-1b + ACS 500
or vs IL-1b + ACS 1000: P Q 0.05) (Fig. 1).
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not affect total coll-II production in culture media
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IL-1b (2 IU/ml) induces a significant decrease of
total coll-II production in culture media (0–16
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Fig. 5. Total PGE2 production in culture medium by
human chondrocytes cultivated in clusters in the
presence of ACS 2 IL-1b during the first 16 days of
culture. b and c vs a; c and d v b; c v d: P Q 0.05.
Fig. 6. Total PGE2 production in culture medium by
human chondrocytes cultivated in clusters in the
presence of ACS 2 IL-1b from day 16 to day 24. a vs b:
P Q 0.05.
IL-1b (2 IU/ml) induces a significant decrease of
coll-II content inside chondrocyte clusters (at day
32) (IL-1b vs controls: P Q 0.05) (Fig. 4).
When chondrocytes are cultivated in the
presence of ACS and IL-1b, ACS (1000 mg/ml)
counteracts the IL-1b-induced effects (P Q 0.05) in
chondrocyte clusters (Fig. 4).
pge2 production
Three-dimensional culture during the first 16 days
of culture
IL-1b (2 IU/ml) induces a significant increase in
total PGE2 production in culture media (IL-1b vs
controls: P Q 0.05) (Fig. 5).
When compared with untreated controls, total
PGE2 production in media (from day 0 to day 16) is
increased by IL-1b (P Q 0.05) and decreased by ACS
(500 or 1000 mg/ml) (P Q 0.05) (Fig. 5). When
chondrocytes are cultivated in the presence of ACS
and IL-1b, ACS (100, 500 or 1000 mg/ml) signifi-
cantly counteracts the IL-1b-induced effects (IL-1b
vs ACS 100 mg/ml + IL-1b, or vs ACS 500 mg/ml + IL-
1b or vs ACS 1000 mg/ml + IL-1b: P Q 0.05) (Fig. 5).
Three-dimensional culture from day 16 to day 32
After 24 days of culture, PGE2 production in
culture media is not detectable by our radio-
immunoassay (Q20 pg/ml). Fig. 6 represents the
total PGE2 production in culture media from day 16
to day 24.
When chondrocytes are cultivated in the
presence of ACS (100, 500 or 1000 mg/ml), ACS does
not affect total PGE2 production in culture media
(Fig. 6) IL-1b (2 IU/ml) induces a significant
increase of total PGE2 production in culture media
(IL-1b vs controls: P Q 0.05) (Fig. 6).
When chondrocytes are cultivated in the
presence of ACS and IL-1b, ACS (100, 500 or
1000 mg/ml) does not counteract the IL-1b-induced
effects.
acs binding to il-1a or il-1b
There is no binding of ACS to IL-1a or IL-1b
(Table III).
Discussion
In our study, the long-term cluster culture model
[8, 27–29] was used to test the effects of a cartilage
Table III
Binding of ACS to IL-1a and IL-1b
ACS concentration IL-1a binding (%) IL-1b binding (%)
100 102 109
300 110 104
1000 89 118
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GAG, chondroitin sulfate, in the presence or
absence of IL-1b, on human chondrocyte metab-
olism in vitro. These experiments confirm our
previous results [11] and many studies conducted
in various experimental models [30–33]: IL-1b
induces a decrease in cartilage matrix element
production (i.e.: coll-II and PGs) and an increase in
PGE2 synthesis. These effects of IL-1b are stronger
at the beginning of the culture, during the first 2
weeks, than thereafter, from day 16 to day 32.
During the first 2 weeks of culture, the chondro-
cyte cluster is forming and flaky, then it condenses
while its weight and its PG and coll-II contents
increase with culture duration [8]. It is possible
that the access and fixation of IL-1b to its receptors
is facilitated when the cells are surrounded by a
flaky matrix. When the cluster is constituted, the
IL-1b effects are weaker. Indeed, some works have
shown that cartilage matrix is composed of small
PGs (fibromodulin, decorin, biglycan) which are
able to bind cytokines [34] and may decrease the
effects of IL-1b.
Here, we show that ACS increases PG pro-
duction by human chondrocytes in culture media
and in clusters. Moreover, the ACS effects are
stronger during the first 2 weeks of culture than
from day 16 to day 32 when the cluster is
constituted: ACS is more active when chondro-
cytes produce large amounts of matrix elements
and organize their matrix. ACS does not affect
basal coll-II production by chondrocytes. This is
not surprising, since ACS is a cartilage GAG and
might be used as substrate for PG synthesis. Other
works (in other experimental models) have shown
that ACS increases GAG synthesis by chondro-
cytes in vitro [35] and hyaluronic acid synthesis by
synoviocytes in vitro [36].
When ACS is added to the culture medium
during the first days, ACS counteracts the
IL-1b-induced effects. This effect of ACS is stronger
on PG production than on coll-II production. When
ACS is added to culture medium from day 16 to day
32, when the cluster is constituted, ACS counter-
acts the IL-1b effects in a less potent way than
when ACS is added at the beginning of culture.
Concerning PG cluster content, there is a slow
increase with culture duration (for example, in the
presence of 100 mg ACS/ml: PG cluster content
increases from 686.7 2 25.2 ng/mg DNA at day 16 to
840.0 2 35.2 ng/mg DNA at day 32). This slow PG
accumulation in cluster may be due to an effect of
ACS on PG synthesis processes and/or to the
integration of ACS in aggrecan.
Concerning PGE2 production, ACS (at 500 or
1000 mg/ml) decreases total PGE2 production
during the first 16 days of culture. Moreover,
during this culture period, ACS (100–1000 mg/ml)
inhibits the stimulating IL-1b effect on PGE2
production. The large PGE2 release observed at the
beginning of culture and under the effect of IL-1b
is significantly reduced by ACS. Mitrovic et al. [37]
have shown that PGE2 inhibit matrix element
production by chondrocytes in vitro. In our
experimental model, we have previously shown
that shark ACS (10–1000 mg/ml) increases PG
content in clusters and decreases collagenolytic
activity measured in culture media [38]. Baici et al.
[39–41] have shown that ACS partially inhibits
elastase activity (elastase is a potent mediator of
cartilage degradation). Moreover, according to the
latter authors, interaction between elastase and
GAGs seems achieved through electrostatic bonds
between negatively charged sulfate groups and the
enzyme positive charges. However, this interaction
does not influence the enzyme active site, but
induces an indirect loss of its catalytic efficacy.
Kato et al. [42] have shown that another GAG,
hyaluronic acid, forms a viscous barrier protecting
cartilage, inhibiting IL-1-induced PGE2 production
by synoviocytes and decreasing the loss of
cartilage PGs [43–44]. Another hypothesis is that
the electronegative charges of ACS could bind
cytokines responsible for matrix degradation [45].
However, studies measuring specific binding using
IL-1 and ACS (100 to 1000 mg/ml) showed no
binding of ACS to IL-1a or IL-1b. Further
experiments are needed to determine if ACS can
bind other cytokines such as TNFa or IL-6.
Transposition of these in vitro results to in vivo
situation must consider in vivo ACS concen-
trations, particularly the synovial fluid concen-
tration. Actually, total sulfated GAG
concentrations in humans vary according to
pathologies [46–47]: from 80–330 mg/ml in synovial
fluid. ACS-4 and ACS-6 disaccharide assays seem to
indicate 40–100 mg/ml. The ACS (Structum8) ad-
ministration to patients would increase ACS and
total GAG concentrations up to 100 mg/ml. At this
concentration, ACS might inhibit IL-1b-induced
effects in vivo; this hypothesis has to be tested in
in vivo experimental models.
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